Investigation of the Clinical Remission Course in Ulcerative Colitis from Tofacitinib Induction to Tapering or Withdrawal in Japanese Patients: A Single-Center Retrospective Study.

Q2 Medicine
Inflammatory Intestinal Diseases Pub Date : 2025-04-04 eCollection Date: 2025-01-01 DOI:10.1159/000545704
Miki Koroku, Teppei Omori, Shun Murasugi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige, Yousuke Nakai
{"title":"Investigation of the Clinical Remission Course in Ulcerative Colitis from Tofacitinib Induction to Tapering or Withdrawal in Japanese Patients: A Single-Center Retrospective Study.","authors":"Miki Koroku, Teppei Omori, Shun Murasugi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige, Yousuke Nakai","doi":"10.1159/000545704","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tofacitinib (TOF), a Janus kinase inhibitor, has emerged as an innovative treatment option for patients with moderate-to-severe ulcerative colitis (UC). However, the clinical course of patients who achieve induction and maintain remission followed by TOF tapering or withdrawal is unclear. We investigated the efficacy of TOF and the clinical course after TOF tapering or withdrawal in real-world clinical practice.</p><p><strong>Method: </strong>Thirty-two patients treated with TOF 20 mg/day for UC relapse between October 2018 and August 2023 were included in this single-center, retrospective observational study. Disease activity was defined by partial Mayo score (PMS), and remission was defined as PMS ≤2 and rectal bleeding score 0, other score ≤1. PMS before TOF 20 mg/day induction was compared with PMS at 8 weeks. Patients who achieved clinical remission were tapered to 10 mg/day, while those who requested for drug withdrawal were allowed. The relapse rate of the TOF 10 mg/day maintenance group and the TOF withdrawal group was compared. Both groups included patients who had maintained remission at 6 months after tapering TOF to 10 mg/day. In addition, the efficacy of TOF 20 mg/day reinduction therapy was also compared between patients who relapsed in the TOF 10 mg/day maintenance group and the TOF withdrawal group.</p><p><strong>Result: </strong>Twenty-three patients (71.9%) achieved induction of remission by 8 weeks after TOF 20 mg/day administration, with significantly lower PMS than before TOF (<i>p</i> < 0.0001). Ultimately, 27 patients (84.4%) achieved remission, 24 who achieved remission were tapered to 10 mg/day, whereas 18 were able to maintain remission for 6 months. Seven of the 18 eventually withdrew from TOF. There was no significant difference in relapse rates between the TOF 10 mg/day maintenance group (<i>n</i> = 11; follow-up, 525 [29-1,483] days) and the TOF withdrawal group (<i>n</i> = 7; follow-up, 284 [77-797] days) (5/11 [45.5%] vs. 3/7 [42.9%], log-rank test: <i>p</i> = 0.7091). All patients who received TOF 20 mg/day reintroduction therapy after relapse went into remission.</p><p><strong>Conclusion: </strong>In clinical practice, TOF 20 mg/day significantly induced induction of remission, and in patients who received 6 months of maintenance remission therapy with TOF 10 mg/day, the relapse rates between the TOF 10 mg/day maintenance group and the TOF withdrawal group were similar. After relapse, TOF 20 mg/day reintroduction therapy improved symptoms.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"115-124"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083954/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammatory Intestinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000545704","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Tofacitinib (TOF), a Janus kinase inhibitor, has emerged as an innovative treatment option for patients with moderate-to-severe ulcerative colitis (UC). However, the clinical course of patients who achieve induction and maintain remission followed by TOF tapering or withdrawal is unclear. We investigated the efficacy of TOF and the clinical course after TOF tapering or withdrawal in real-world clinical practice.

Method: Thirty-two patients treated with TOF 20 mg/day for UC relapse between October 2018 and August 2023 were included in this single-center, retrospective observational study. Disease activity was defined by partial Mayo score (PMS), and remission was defined as PMS ≤2 and rectal bleeding score 0, other score ≤1. PMS before TOF 20 mg/day induction was compared with PMS at 8 weeks. Patients who achieved clinical remission were tapered to 10 mg/day, while those who requested for drug withdrawal were allowed. The relapse rate of the TOF 10 mg/day maintenance group and the TOF withdrawal group was compared. Both groups included patients who had maintained remission at 6 months after tapering TOF to 10 mg/day. In addition, the efficacy of TOF 20 mg/day reinduction therapy was also compared between patients who relapsed in the TOF 10 mg/day maintenance group and the TOF withdrawal group.

Result: Twenty-three patients (71.9%) achieved induction of remission by 8 weeks after TOF 20 mg/day administration, with significantly lower PMS than before TOF (p < 0.0001). Ultimately, 27 patients (84.4%) achieved remission, 24 who achieved remission were tapered to 10 mg/day, whereas 18 were able to maintain remission for 6 months. Seven of the 18 eventually withdrew from TOF. There was no significant difference in relapse rates between the TOF 10 mg/day maintenance group (n = 11; follow-up, 525 [29-1,483] days) and the TOF withdrawal group (n = 7; follow-up, 284 [77-797] days) (5/11 [45.5%] vs. 3/7 [42.9%], log-rank test: p = 0.7091). All patients who received TOF 20 mg/day reintroduction therapy after relapse went into remission.

Conclusion: In clinical practice, TOF 20 mg/day significantly induced induction of remission, and in patients who received 6 months of maintenance remission therapy with TOF 10 mg/day, the relapse rates between the TOF 10 mg/day maintenance group and the TOF withdrawal group were similar. After relapse, TOF 20 mg/day reintroduction therapy improved symptoms.

溃疡性结肠炎患者从托法替尼诱导到逐渐减量或停药的临床缓解过程的调查:一项单中心回顾性研究。
简介:托法替尼(TOF)是一种Janus激酶抑制剂,已成为中重度溃疡性结肠炎(UC)患者的创新治疗选择。然而,达到诱导并维持缓解后TOF逐渐减少或停药的患者的临床过程尚不清楚。我们在现实世界的临床实践中调查了TOF的疗效和TOF逐渐减少或停药后的临床过程。方法:2018年10月至2023年8月期间,32例UC复发患者接受TOF 20mg /d治疗,纳入该单中心回顾性观察研究。疾病活动性以部分梅奥评分(PMS)定义,缓解定义为PMS≤2分,直肠出血评分0分,其他评分≤1分。比较TOF 20mg /天诱导前的PMS与8周时的PMS。达到临床缓解的患者逐渐减少到10毫克/天,而那些要求停药的患者则被允许。比较TOF 10mg /d维持组和TOF停药组的复发率。两组患者均在TOF逐渐减少至10mg /天后6个月维持缓解。此外,还比较了TOF 10mg /天维持组和停药组复发患者TOF 20mg /天再诱导治疗的疗效。结果:TOF 20mg /d给药后8周,23例患者(71.9%)达到诱导缓解,PMS明显低于TOF前(p < 0.0001)。最终,27名患者(84.4%)获得缓解,24名患者的缓解量逐渐减少到10mg /天,而18名患者的缓解期维持了6个月。18人中有7人最终退出了TOF。TOF 10mg /天维持组的复发率无显著差异(n = 11;随访525[29- 1483]天)和TOF停药组(n = 7;随访284[77-797]天)(5/11[45.5%]对3/7 [42.9%],log-rank检验:p = 0.7091)。所有复发后接受TOF 20mg /天再引入治疗的患者均获得缓解。结论:在临床实践中,TOF 20mg /天显著诱导缓解诱导,在接受TOF 10mg /天维持缓解治疗6个月的患者中,TOF 10mg /天维持组与TOF停药组的复发率相似。复发后,TOF 20mg /天重新引入治疗可改善症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Inflammatory Intestinal Diseases
Inflammatory Intestinal Diseases Medicine-Gastroenterology
CiteScore
4.50
自引率
0.00%
发文量
6
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信